Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
admin 3rd August 2017 Uncategorised 0Jazz won a month-early approval for Vyxeos, the first treatment for patients with certain types of high-risk acute myeloid leukemia (AML). A perennial subject of buyout talk, Jazz has impressed investors this year, and some analysts think it could make buys of its own.
More: Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
Source: fierce